Richard Elliott

3.4k total citations · 1 hit paper
47 papers, 2.4k citations indexed

About

Richard Elliott is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Richard Elliott has authored 47 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 15 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Richard Elliott's work include PARP inhibition in cancer therapy (7 papers), DNA Repair Mechanisms (6 papers) and Cell Image Analysis Techniques (6 papers). Richard Elliott is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), DNA Repair Mechanisms (6 papers) and Cell Image Analysis Techniques (6 papers). Richard Elliott collaborates with scholars based in United Kingdom, United States and Australia. Richard Elliott's co-authors include Christopher J. Lord, Alan Ashworth, Nicholas C. Turner, Ilirjana Bajrami, Sydonia Rayter, Elizabeth Iorns, Andrew Tutt, Farah Rehman, Julia Boshuizen and Bing Wang and has published in prestigious journals such as Physical Review Letters, Advanced Materials and Journal of Biological Chemistry.

In The Last Decade

Richard Elliott

46 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

2016 511 citations María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Elliott United Kingdom	24	1.4k	1.2k	555	303	209	47	2.4k
Natalia Jura United States	25	2.1k 1.5×	1.3k 1.0×	375 0.7×	248 0.8×	107 0.5×	50	3.2k
Sarajane Ross United States	23	2.0k 1.5×	1.2k 1.0×	524 0.9×	327 1.1×	76 0.4×	37	3.1k
Mahaveer S. Bhojani United States	23	1.4k 1.0×	749 0.6×	331 0.6×	305 1.0×	100 0.5×	37	2.8k
W. Nathaniel Brennen United States	23	948 0.7×	908 0.7×	404 0.7×	505 1.7×	70 0.3×	49	2.1k
Todd A. Aguilera United States	20	1.4k 1.1×	809 0.7×	454 0.8×	358 1.2×	126 0.6×	72	3.3k
Attila Nagy United States	34	1.4k 1.0×	1.3k 1.1×	368 0.7×	188 0.6×	195 0.9×	78	3.5k
Adam P. Silverman United States	21	2.3k 1.7×	1.4k 1.1×	132 0.2×	313 1.0×	206 1.0×	36	3.2k
Kenneth L. Pitter United States	24	2.3k 1.7×	735 0.6×	276 0.5×	683 2.3×	162 0.8×	48	4.2k
Susan D. Spencer United States	24	2.0k 1.4×	1.7k 1.4×	519 0.9×	166 0.5×	163 0.8×	36	5.5k
Rodney B. Luwor Australia	32	2.0k 1.5×	1.5k 1.2×	428 0.8×	867 2.9×	164 0.8×	95	3.7k

Countries citing papers authored by Richard Elliott

Since Specialization

Citations

This map shows the geographic impact of Richard Elliott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Elliott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Elliott more than expected).

Fields of papers citing papers by Richard Elliott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Elliott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Elliott. The network helps show where Richard Elliott may publish in the future.

Co-authorship network of co-authors of Richard Elliott

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Elliott. A scholar is included among the top collaborators of Richard Elliott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Elliott. Richard Elliott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hollis, Robert L., Richard Elliott, John C. Dawson, et al.. (2024). High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecologic Oncology. 186. 42–52. 5 indexed citations

Elliott, Richard, John C. Dawson, Susan M. Anderson, et al.. (2024). Morphological profiling in human neural progenitor cells classifies hits in a pilot drug screen for Alzheimer’s disease. Brain Communications. 6(2). fcae101–fcae101. 5 indexed citations

Quintanilla, Andrea, Richard Elliott, John C. Dawson, et al.. (2023). Discovery of senolytics using machine learning. Nature Communications. 14(1). 3445–3445. 67 indexed citations

Valero, Teresa, Álvaro Lorente‐Macías, David Jonathan Bennett, et al.. (2023). Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells. RSC Medicinal Chemistry. 14(12). 2611–2624. 2 indexed citations

Elliott, Richard, et al.. (2023). A cautionary note on the use of N-acetylcysteine as a reactive oxygen species antagonist to assess copper mediated cell death. PLoS ONE. 18(12). e0294297–e0294297. 6 indexed citations

Ravikumar, Balaguru, Richard Elliott, John C. Dawson, et al.. (2023). Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells. iScience. 26(7). 107209–107209. 4 indexed citations

Elliott, Richard, et al.. (2021). High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need. Cell chemical biology. 28(3). 338–355. 32 indexed citations

Elliott, Richard, et al.. (2020). High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery. SLAS DISCOVERY. 25(7). 770–782. 16 indexed citations

Chong, Irene, Lauren I. Aronson, Aditi Gulati, et al.. (2017). Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut. 67(10). 1780–1792. 16 indexed citations

10.

Jones, Samuel E., Emmy D.G. Fleuren, Jessica Frankum, et al.. (2017). ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer Research. 77(24). 7014–7026. 47 indexed citations

11.

Herrera-Abreu, María Teresa, Marta Palafox, Uzma Asghar, et al.. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 76(8). 2301–2313. 511 indexed citations breakdown →

12.

Beck, Daniel, Ruth Barber, Siân Evans, et al.. (2016). Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. Journal of Biological Chemistry. 291(32). 16686–16698. 12 indexed citations

13.

Aarts, Marieke, Ilirjana Bajrami, María Teresa Herrera-Abreu, et al.. (2015). Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Molecular Cancer Therapeutics. 14(4). 865–876. 48 indexed citations

14.

Shen, Yuqiao, Farah Rehman, Ying Feng, et al.. (2013). BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency. Clinical Cancer Research. 19(18). 5003–5015. 378 indexed citations

15.

Hewish, Madeleine, Sarah A. Martin, Richard Elliott, et al.. (2013). Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. British Journal of Cancer. 108(4). 983–992. 27 indexed citations

16.

Rehman, Farah, Richard Elliott, Rachel Brough, et al.. (2012). Developing rational drug combination strategies for PARP inhibitors.. Journal of Clinical Oncology. 30(15_suppl). 3050–3050. 1 indexed citations

17.

Spiers, Mary, et al.. (2008). Sex Differences in Spatial Object-Location Memory in a Virtual Grocery Store. CyberPsychology & Behavior. 11(4). 471–473. 22 indexed citations

18.

Rayter, Sydonia, Richard Elliott, Jon Travers, et al.. (2007). A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene. 27(8). 1036–1044. 66 indexed citations

19.

Elliott, Richard, Igal Szleifer, & M. Schick. (2007). A Microscopic Model Calculation of the Phase Diagram of Ternary Mixtures of Cholesterol and Saturated and Unsaturated Phospholipids. Methods in molecular biology. 398. 303–317. 3 indexed citations

20.

Brimble, Margaret A. & Richard Elliott. (1997). Addition of silyloxydienes to 2-substituted 1,4-benzoquinones and 1,4-naphthoquinones. Tetrahedron. 53(22). 7715–7730. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact